LeonaAnnHolmbergMD

Oncology • Seattle, WA

Associate Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Holmberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Holmberg's full profile

Already have an account?

Office
NE Pacific St
# 1959
Seattle, WA 98195
Phone+1 206-288-1000

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1992
University of RochesterResidency, Internal Medicine, 1986 - 1987
University of Miami Leonard M. Miller School of MedicineClass of 1986

Certifications & Licensure

HI State Medical License 2018 - 2026
WA State Medical License 1989 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma Start of enrollment: 2001 Aug 01
Completed
Phase 2
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 1, Phase 2
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Start of enrollment: 2008 Aug 08
Completed
Phase 2
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant Start of enrollment: 2009 Feb 01
Completed
Phase 2
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Start of enrollment: 2010 Sep 02
Completed
Phase 2
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells Start of enrollment: 2010 Nov 09
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Te...
George E Georges, Dinesh Khanna, Mark H Wener, Matthew G Mei, Maureen D Mayes
Arthritis & Rheumatology. 2024-12-03
CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation.
Danniel Zamora, Hu Xie, Alicja Sadowska-Klasa, Eleftheria Kampouri, Melinda A Biernacki
Blood Advances. 2024-09-10
1 citations
Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization.
Andrew J Portuguese, Albert C Yeh, Rahul Banerjee, Leona Holmberg, Natalie Wuliji
Transplantation and Cellular Therapy. 2024-08-01

Journal Articles

Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma
Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica

Lectures

Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018